intestin
lymphat
transport
shown
absorpt
pathway
follow
oral
administr
lipid
increas
number
lipophil
drug
absorb
diffus
across
intestin
enterocyt
transit
associ
secret
enterocyt
lipoprotein
chylomicronassoci
drug
secret
enterocyt
lymphat
circul
rather
portal
circul
thu
avoid
metabolicallyact
liver
still
ultim
return
system
circul
parallel
potenti
altern
absorpt
pathway
firstpass
metabol
reduc
increas
lymphat
drug
exposur
open
potenti
novel
therapeut
modal
allow
implement
lipidbas
drug
deliveri
system
review
discuss
physiolog
featur
lymphat
enterocyt
uptak
metabol
link
drug
transport
lipid
digestionreacyl
experiment
model
vivo
vitro
silico
lymphat
transport
design
lipidor
prodrugbas
drug
deliveri
system
enhanc
lymphat
drug
transport
drug
discoveri
program
pharmaceut
industri
continu
gener
increasingli
potent
drug
enter
develop
pipelin
howev
increas
drug
potenc
often
come
decreas
eas
design
drug
deliveri
system
conveni
oral
administr
due
gener
undesir
increas
molecular
weight
lipophil
log
octanolwat
partit
coeffici
log
p
decreas
water
solubl
oral
administ
drug
gener
enter
system
circul
sequenti
transit
intestin
epitheli
cell
call
enterocyt
enter
portal
circul
expos
metabolicallyact
liver
howev
highli
lipophil
drug
log
p
n
longchain
triglycerid
tg
solubl
mgg
entri
portal
circul
reduc
rel
entri
lymphat
circul
transit
across
enterocyt
highli
lipophil
drug
associ
secret
enterocyt
lipoprotein
specif
chylomicron
chylomicronassoci
drug
secret
mesenter
lymphat
circul
rather
portal
circul
lead
directli
metabolicallyact
liver
ultim
join
mix
blood
system
circul
therefor
drug
lymphaticallyrath
portallytransport
avoid
firstpass
metabol
liver
turn
increas
drug
concentr
lymph
duct
node
site
therapeut
drug
action
therapeut
benefit
mind
fact
drug
increasingli
physicochem
characterist
suitabl
lymphat
transport
import
understand
factor
affect
lymphat
drug
transport
review
discuss
structur
physiolog
featur
lymphat
enterocyt
uptak
metabol
link
drug
transport
lipid
digestionreacyl
pathway
experiment
model
lymphat
transport
design
lipidor
prodrugbas
drug
deliveri
system
enhanc
lymphat
drug
transport
lymphat
system
exist
part
bodi
except
central
nervou
system
major
part
system
bone
marrow
spleen
thymu
gland
lymph
nodesnodul
tonsil
organ
includ
heart
lung
intestin
liver
skin
also
contain
lymphat
tissu
system
ultim
respons
transport
lymph
wateri
clear
fluid
throughout
bodi
lymph
distribut
lymphocyt
immun
cell
variou
immunerel
factor
lymphocyt
immun
cell
function
import
protect
bodi
antigen
invad
attack
bodi
virus
andor
bacteria
lymphat
system
thought
import
drainag
system
actual
collect
drainag
fluid
cell
tissu
later
return
fluid
back
circul
blood
pool
therefor
accept
definit
lymph
fluid
protein
filter
extractedsqueez
blood
ie
blood
plasma
role
lymphat
system
fat
absorpt
transport
also
major
function
compon
lymphat
system
order
appreci
import
function
gener
understand
lymphat
system
anatomi
need
duct
lymphat
system
interconnect
lymph
organ
includ
bone
marrow
lymph
node
spleen
well
thymu
gland
lymph
within
duct
transport
lymphocyt
immun
cell
blymphocyt
bcell
tlymphocyt
tcell
origin
precursor
cell
bone
marrow
bcell
matur
bone
marrow
tcell
matur
thymu
gland
move
lymphat
duct
respect
intestin
absorpt
transport
lipid
duct
lymphat
system
interconnect
lymph
organ
also
fairli
import
provid
transport
protein
fat
substanc
lymph
transport
typic
begin
blindend
vessel
found
tissu
term
lymph
capillari
creat
capillari
system
lymph
drain
lymph
capillari
highli
permeabl
pressur
allow
lymph
fluid
drain
easili
tissu
lymph
capillari
therefor
lymph
vessel
form
network
throughout
bodi
overal
lymphat
system
function
unidirect
manner
lymph
drain
tissu
return
system
blood
subclavian
blood
vessel
thorac
lymph
duct
join
content
mix
prior
entri
heart
intestin
lymphat
system
pathway
fatsolubl
vitamin
foodderiv
lipid
typic
western
diet
g
per
day
waterinsolubl
peptidelik
molecul
transport
system
circul
drug
transport
via
intestin
lymphat
system
bypass
liver
thu
avoid
hepat
firstpass
metabol
stay
within
scope
paper
mechan
drug
enter
intestin
lymph
follow
oral
administr
complex
simplifi
follow
firstli
typic
intestin
tract
richli
suppli
blood
lymph
lamina
propia
surround
enterocyt
close
proxim
blood
lymph
vessel
absorb
transit
across
enterocyt
two
potenti
scenario
occur
one
situat
drug
prefer
entri
blood
capillari
entri
lymph
capillari
favor
former
pathway
absorb
drug
transport
portal
blood
common
mechan
high
rate
fluid
flow
portal
blood
compar
intestin
lymph
higher
portal
blood
largehigh
molecular
weight
drug
limit
unabl
diffus
across
blood
capillari
thu
util
permeabl
lymphat
capillari
absorpt
upon
entri
enterocyt
lipoprotein
critic
bind
macromolecul
aid
entri
process
importantli
facilit
movement
across
enterocyt
sinc
physic
size
lipoprotein
vari
subsequ
limit
whether
diffus
across
vascular
endothelium
furthermor
lipoprotein
size
limit
diffus
remain
unobstruct
diffus
across
lymphat
capillari
result
preferenti
access
lipoprotein
along
drug
lymphat
fig
intestin
lymphat
drug
transport
exhibit
number
advantag
oral
absorpt
via
portal
blood
instanc
drug
transport
via
intestin
lymphat
system
enter
system
circul
without
first
pass
liver
advantag
drug
highli
metabol
first
pass
liver
sinc
increas
oral
bioavail
also
observ
intestin
lymphat
transport
affect
local
exposur
lymphat
ultim
system
exposur
possibl
obtain
differ
toxicolog
profil
intestin
lymphat
transport
also
report
effect
immunomodulatori
chemotherapeut
drug
sinc
lymphat
system
primari
rout
metastasi
solid
tumor
transport
pathway
b
lymphocyt
furthermor
recent
suggest
develop
sequestr
spread
human
immunodefici
viru
hiv
hepat
b
c
viru
morbilliviru
canin
distemp
viru
sever
acut
respiratori
syndrom
sar
associ
coronaviru
associ
lymphocyt
present
lymph
lymphoid
tissu
therefor
lipid
prodrug
didanosin
antivir
target
aid
develop
enhanc
lymphat
deliveri
digest
absorpt
lipid
link
intestin
drug
transport
process
digest
absorpt
lipid
review
howev
recommend
reader
consid
excel
report
cover
process
detail
process
digest
foodderiv
lipid
predominantli
form
triglycerid
start
stomach
preduoden
lingual
mouth
caviti
gastric
acid
lipas
gastric
mucosa
hydrolyz
triglycerid
diglycerid
fatti
acid
initi
hydrolysi
action
acid
lipas
result
byproduct
remain
solid
materi
migrat
stomach
pass
pylor
antrum
pylor
antrum
gastric
chyme
releas
combin
peristalt
movement
result
emulsif
foodderiv
triglycerid
empti
duodenum
presenc
lipid
duodenum
stimul
secret
pancreat
fluid
bile
bile
salt
bile
lipid
biliari
lipid
phospholipid
cholesterol
adher
surfac
emuls
form
colloidallik
stabl
emuls
smaller
droplet
size
higher
surfac
area
allow
better
action
pancreat
lipas
allow
hydrolysi
triglycerid
two
fatti
acid
molecul
triglycerid
phospholipid
cholesterol
also
get
digest
intestin
phospholipid
digest
occur
small
intestin
gastric
lipas
incap
digest
phospholipid
phospholipid
mainli
found
bile
phosphatidylcholin
mix
micel
cholesterol
bile
salt
bile
releas
small
intestin
phosphatidylcholin
hydrolyz
phospholipas
fatti
acid
lysophosphatidylcholin
cholesteryl
ester
get
hydrolyz
cholesterol
esteras
small
intestin
free
cholesterol
cholesterol
esteras
activ
enhanc
presenc
trihydroxi
bile
salt
sodium
cholat
also
allow
selfaggreg
enzym
polymer
form
digest
product
releas
triglycerid
droplet
colloid
emuls
form
liquid
crystallin
structur
combin
suffici
concentr
bile
salt
produc
unilamellar
miltilamellar
vesicl
accordingli
postprandi
intestin
lumen
higher
bile
salt
due
higher
bile
releas
greater
presenc
unilamellar
miltilamellar
vesicl
lipid
digest
product
contain
mix
bile
saltphospholipid
micellar
phase
first
need
dissoci
phase
order
absorb
pass
enterocyt
report
enterocyt
surfac
might
proxim
low
ph
region
allow
chang
colloid
structur
lead
releas
apic
absorpt
lipid
digest
product
transport
lipid
digest
product
across
apic
membran
enterocyt
report
occur
via
passiv
transport
via
activ
transport
use
specif
membranebound
carrier
protein
passiv
transport
predomin
lumin
lipid
concentr
high
case
postprandi
membranebound
carrier
protein
involv
fatti
acid
uptak
involv
microvillu
membran
fatti
acid
bind
protein
fatti
acid
transport
lipid
absorb
enterocyt
chain
length
determin
subsequ
intracellular
process
shortand
mediumchain
lipid
c
b
gener
diffus
across
enterocyt
longchain
lipid
c
gener
migrat
endoplasm
reticulum
get
reacyl
assembl
lipoprotein
secret
mesenter
lymph
reacyl
process
fatti
acid
monoglycerid
triglycerid
endoplasm
reticulum
report
involv
two
cytosol
fatti
acid
bind
protein
ifabp
lfabp
furthermor
reacyl
process
appear
occur
via
two
possibl
pathway
one
pathway
involv
twostep
sequenti
direct
acyl
triglycerid
account
main
pathway
product
triglycerid
destin
chylomicron
second
minor
pathway
phospatid
acid
pathway
involv
sequenti
acyl
endogen
three
molecul
activ
fatti
acid
account
product
triglycerid
mainli
destin
low
densiti
lipoprotein
vldl
sequenti
step
digest
lipid
absorpt
via
portal
blood
mesenter
lymph
repres
fig
somewhat
narrow
focu
review
briefli
review
lipoprotein
assembl
howev
direct
interest
reader
number
recent
review
contain
detail
inform
topic
chylomicron
vldl
primari
lipoprotein
secret
intestin
chylomicron
appear
predomin
lipoprotein
postprandi
condit
higher
lipid
load
vldl
appear
predomin
lipoprotein
preprandi
condit
low
lipid
load
furthermor
report
assembl
intestin
chylomicron
vldl
occur
two
separ
independ
pathway
first
step
lipoprotein
assembl
involv
synthesi
apob
rough
endoplasm
reticulum
associ
phospholipid
deriv
endoplasm
reticulum
membran
neutral
triglycerid
lipid
ad
apob
phospholipid
complex
form
primordi
lipoprotein
releas
lumen
endoplasm
reticulum
size
primordi
lipoprotein
depend
length
apob
polypeptid
next
step
format
larg
triglyceriderich
lipid
droplet
smooth
endoplasm
reticulum
independ
apob
preval
lumin
lipid
challeng
postprandi
last
step
involv
fusion
primordi
lipoprotein
assembl
rough
endoplasm
reticulum
triglyceriderich
lipid
droplet
form
smooth
endoplasm
reticulum
process
call
core
expans
like
occur
junction
rough
smooth
endoplasm
reticulum
apob
present
lipid
droplet
would
accumul
enterocyt
factor
determin
chylomicron
vldl
produc
resid
amount
lipid
ad
primordi
lipoprotein
core
expans
amount
avail
foodderiv
lipid
format
lipoprotein
intestin
lymphat
drug
transport
significantli
increas
expect
food
consumpt
howev
substanti
amount
endogen
lipid
free
fatti
acid
attach
phospholipid
triglycerid
avail
enterocyt
fast
condit
describ
endogen
fatti
acid
access
enterocyt
apic
lumin
basolater
side
endogen
fatti
acid
access
apic
side
deriv
either
desquam
enterocyt
bile
deposit
fatti
acid
necessari
phospholipid
transport
endogen
fatti
acid
access
basolater
side
deriv
uptak
chylomicron
fatti
acid
present
remain
intestin
blood
suppli
howev
recent
de
novo
synthesi
rout
present
plausibl
sourc
endogen
fatti
acid
enterocyt
fast
condit
main
contribut
endogen
fatti
acid
bile
follow
minor
contribut
enterocyt
desquam
minim
contribut
de
novo
synthesi
within
enterocyt
bile
play
critic
role
solubil
intestin
absorpt
lipophil
drug
foodderiv
lipid
format
transient
mix
micel
bile
salt
phospholipid
enterocyt
endogen
fatti
acid
reesterifi
triglycerid
selfassembl
lipoprotein
effect
food
system
exposur
coadminist
drug
report
varieti
drug
instanc
transport
testosteron
undecano
highli
lipophil
prodrug
testosteron
system
exposur
testosteron
studi
greyhound
dog
postprandi
administr
determin
testosteron
undecano
prodrug
transport
lymphat
intact
hydrolyz
testosteron
system
circul
human
testosteron
undecano
exhibit
higher
system
exposur
testosteron
testosteron
given
fed
subject
exposur
testosteron
prodrug
higher
fed
subject
compar
fast
subject
increas
postprandi
system
exposur
correl
enhanc
lymphat
transport
increas
lumin
solubil
testosteron
undecano
anoth
instanc
effect
food
shown
lymphat
transport
halofantrin
free
base
preand
postprandi
state
assess
dog
result
show
cumul
postprandi
lymphat
transport
halofantrin
administ
dose
preprandi
cumul
lymphat
transport
equal
administ
dose
show
fig
hydrochlorid
salt
halofantrin
administ
dog
similar
cumul
postprandi
lymphat
transport
achiev
would
indic
halofantrin
convert
hydrochlorid
salt
poorli
lipid
solubl
free
base
highli
lipid
solubl
absorpt
enterocyt
convers
report
favor
gastrointestin
ph
would
allow
free
base
associ
lipid
digest
product
would
incorpor
chylomicron
lipoprotein
assembl
vldl
lipoprotein
produc
fast
small
intestin
meal
small
intestin
mainli
produc
chylomicron
differ
vldl
chylomicron
resid
size
nm
diamet
vldl
nm
chylomicron
svedberg
flotat
sf
rate
vldl
chylomicron
type
fatti
acid
infus
intraduoden
also
determin
output
transport
vldl
chylomicron
indic
produc
via
differ
pathway
instanc
palmit
infus
increas
vldl
transport
chang
output
chylomicron
output
increas
linol
oleat
infus
differ
well
document
due
presenc
differ
pathway
assembl
vldl
chylomicron
apo
secret
liver
apo
secret
small
intestin
encod
gene
possibl
genet
disord
affect
apo
b
synthesi
chylomicron
vldl
format
alter
intestin
lymphat
transport
instanc
abetalipoproteinemia
bassenkornzweig
syndrom
rare
genet
disord
complet
failur
liver
gut
produc
triglyceriderich
lipoprotein
chylomicron
vldl
although
origin
believ
caus
apo
b
synthesi
defici
later
confirm
caus
mutat
microsom
triglycerid
transfer
protein
gene
anderson
diseas
chylomicron
retent
disord
anoth
rare
hereditari
hypocholesterolem
syndrom
character
absenc
chylomicron
intercellular
space
although
observ
chylomicron
enterocyt
underli
mechan
anderson
diseas
fulli
understood
yet
patient
nt
defect
gene
involv
apoprotein
synthesi
microsom
triglycerid
transfer
protein
howev
describ
anderson
diseas
might
caus
postgolgi
cargospecif
secret
defect
recent
report
might
link
gene
mutat
lymph
node
undergo
hyperplasia
respons
diseas
process
histolog
chang
occur
lead
increas
lymphat
flow
rate
local
perfus
capillari
permeabl
furthermor
lymphat
system
primari
rout
metastasi
solid
tumor
possibl
complet
obstruct
lymphat
pathway
may
occur
would
lead
slower
lymph
flow
ultim
caus
lymphedema
lymphat
insuffici
howev
metastasi
usual
lead
appear
lymphoma
gut
constitut
larg
proport
human
tumor
usual
inoper
furthermor
decreas
lymph
return
describ
occur
due
lymphat
hypoplasia
aplasia
also
call
primari
lymphedema
obliter
lymph
node
trunk
describ
secondari
lymphedema
disturb
lymph
angiogenesi
report
recent
lymphedemaangiodysplasia
syndrom
anim
model
employ
studi
lymphat
drug
transport
cannul
intestin
lymphat
duct
direct
measur
drug
concentr
type
cannul
requir
irrevers
surgeri
intestin
lymphat
drug
transport
studi
directli
way
human
commonli
use
model
rat
larg
speci
dog
pig
sheep
also
use
mention
approach
studi
lymphat
drug
transport
use
lymph
ductcannul
anim
model
allow
complet
collect
lymph
flow
cannula
collect
lymph
allow
accur
estim
total
extent
lymphat
drug
transport
anoth
approach
use
lymphaticven
shunt
allow
collect
lymph
longer
period
time
fix
time
point
assess
concentrationtim
profil
howev
latter
approach
might
limit
applic
due
low
lymph
flow
rate
limit
sampl
volum
obtain
recent
indirect
pharmacolog
approach
describ
util
intestin
chylomicron
flow
inhibitor
colchicin
approach
system
drug
exposur
compar
presenc
absenc
coadminist
colchicin
indirectli
assess
impact
intestin
lymphat
drug
transport
oral
bioavail
approach
advantag
nt
requir
lymph
ductcannul
howev
impact
block
chylomicron
flow
lipid
process
synthesi
fulli
character
instanc
lower
plasma
vldl
lowdens
lipoprotein
cholesterol
reduc
lipid
apoprotein
secret
nonetheless
employ
cannula
still
common
approach
small
larg
anim
model
rat
common
small
anim
speci
util
due
eas
handl
low
space
requir
hous
studi
perform
anesthet
rat
consciou
restrain
unrestrain
model
also
describ
unconsci
anesthet
rat
model
use
variou
studi
variou
degre
modif
site
cannul
lymph
fistul
feed
rehydr
preand
postop
procedur
dose
model
well
describ
elsewher
briefli
triplecannul
carotid
arteri
system
blood
collect
mesenter
lymph
duct
intestin
lymph
collect
duodenum
administr
rehydr
solut
perform
howev
also
includ
fourth
cannula
jugular
vein
intraven
administr
requir
mesenter
lymph
cannula
allow
collect
lymph
drain
duodenum
consequ
total
amount
drug
transport
lymphat
calcul
system
blood
collect
carotid
arteri
allow
calcul
system
plasma
exposur
interpret
absorpt
drug
via
portal
blood
advantag
allow
assess
portal
blood
absorpt
contribut
bioavail
compar
plasma
exposur
oral
administ
drug
rat
lymph
ductcannul
rat
plasma
exposur
intraven
administ
drug
rat
lymph
ductcannul
rat
expect
anim
model
employ
cannul
common
complic
cannula
occlus
typic
greater
anim
allow
move
freeli
occlus
also
attribut
differ
gastric
motil
empti
lymph
flow
rate
unconsci
anesthet
mlh
consciou
unanesthet
rat
mlh
depend
lymph
volum
sampl
robust
experi
may
requir
long
period
anesthesia
longer
h
produc
signific
logist
concern
maintain
monitor
anim
anesthesia
long
also
produc
signific
increas
mortal
consciou
restrain
rat
model
anim
allow
recov
surgic
anesthesia
place
har
restrain
cage
model
requir
cannula
jugular
vein
system
blood
collect
mesenter
lymph
duct
intestin
lymph
collect
intraduoden
cannula
requir
rehydr
salin
solut
administ
intraven
jugular
vein
cannula
compound
administ
intraven
rat
restrain
lymph
jugular
vein
cannula
advanc
skin
extern
dorsal
back
neck
skin
connect
swivel
continu
sampl
even
though
model
offer
advantag
normal
lymph
flow
rate
gastric
empti
lipid
digest
consciou
rat
unconsci
rat
model
physic
restraint
affect
lymph
flow
rate
gastrointestin
function
produc
venou
return
possibl
complic
consciou
unrestrain
model
also
develop
allow
intraven
oral
administr
compound
continu
lymph
collect
h
system
blood
collect
h
surgic
procedur
includ
tripl
cannula
mesenter
lymph
duct
lymph
collect
carotid
arteri
system
blood
collect
duodenum
overnight
rehydr
order
assess
oral
bioavail
noncannul
rat
mesenter
lymph
ductcannula
includ
well
anoth
oral
administ
group
rat
maintain
two
cannula
carotid
arteri
duodenum
third
group
intraven
administ
rat
via
jugular
vein
cannula
includ
assess
absolut
bioavail
system
blood
collect
via
carotid
arteri
cannula
administr
rehydr
solut
via
intraduoden
cannula
three
rat
model
unconsci
consciou
restrain
consciou
unrestrain
employ
surgic
procedur
perform
nonfast
anim
easier
visual
mesenter
lymph
duct
howev
anim
fast
postop
recoveri
period
allow
lymph
triglycerid
level
return
fast
basal
level
dose
surgic
methodolog
cannul
postop
recoveri
care
rat
well
describ
elsewher
despit
wide
use
rat
consider
limit
instanc
rat
continu
rather
intermitt
flow
bile
intestin
like
human
render
rat
less
clinicallyrelev
dog
pig
similar
biliari
secret
transit
profil
gastrointestin
tract
human
addit
rat
suitabl
model
assess
postprandi
lymphat
transport
sinc
possibl
train
rat
eat
command
rat
diet
significantli
lower
amount
lipid
human
rat
human
rat
gallbladd
thu
pulsatil
postprandi
releas
bile
furthermor
unlik
rat
larg
speci
pig
sheep
dog
allow
administr
clinicallyrelev
dose
formul
amen
studi
monitoredcontrol
fast
fed
condit
report
limit
rat
model
larg
speci
dog
pig
sheep
describ
improv
assess
lymphat
drug
transport
dog
model
dog
wide
use
larg
anim
model
studi
lymphat
drug
transport
similar
gastrointestin
physiolog
human
feasibl
assess
postprandi
lymphat
transport
dog
model
origin
implement
cannul
thorac
duct
either
use
tshape
silicon
rubber
cannula
doublelumen
cannula
howev
cannula
requir
continu
infus
heparan
salin
prevent
clot
surgic
thoracotomi
access
thorac
duct
surgic
procedur
usual
produc
longer
postop
recoveri
period
prevent
need
surgic
thoracotomi
anoth
model
employ
insert
cannula
ligat
isol
segment
extern
jugular
vein
entri
thorac
duct
vein
allow
chronic
collect
lymph
surgic
procedur
difficult
high
incid
pneurothorax
obstruct
venou
return
caval
bifurc
triplecannul
dog
model
implement
collect
lymph
via
cannula
thorac
duct
collect
blood
via
cannula
hepat
portal
vein
venou
blood
via
jugular
vein
model
also
implement
allow
collect
venou
blood
via
cannula
cephal
vein
assess
lymphat
drug
transport
first
past
metabol
via
collect
lymph
blood
cannula
thorac
lymph
duct
hepat
portal
vein
respect
surgic
methodolog
cannul
postop
recoveri
care
dog
well
describ
elsewher
even
though
dog
commonli
employ
larg
anim
model
pig
sheep
also
report
suitabl
model
also
limit
pig
model
pig
exhibit
mani
similar
gastrointestin
tract
compar
human
reason
anesthet
consciou
pig
model
develop
assess
absorpt
lymphat
transport
drug
anesthet
pig
model
involv
oral
administr
lipophil
dye
sudan
black
improv
visual
mesenter
lymph
duct
cannul
also
permit
simultan
sampl
hepat
portal
blood
system
blood
one
disadvantag
model
nt
allow
cumul
assess
lymphat
transport
allow
period
sampl
instead
continu
collect
limit
like
account
model
wide
employ
consciou
pig
model
involv
use
extern
thorac
ductven
shunt
allow
return
thorac
lymph
system
circul
model
employ
assess
lymphat
transport
protein
similar
anesthet
model
nt
permit
cumul
assess
lymphat
transport
allow
period
sampl
instead
continu
sampl
consciou
model
describ
assess
lymphat
transport
protein
administ
subcutan
sheep
lymph
collect
directli
cannula
locat
thorac
lymph
duct
howev
differ
physiolog
complex
sheep
rumin
human
monogastr
signific
applic
model
limit
wide
util
intestin
permeabl
model
use
cell
appli
assess
intracellular
lipoprotein
assembl
well
determin
effect
lipid
lipid
excipi
drug
associ
lipoprotein
lymphat
transport
also
appli
assess
genet
express
posttransl
modif
apolipoprotein
model
assess
assembl
chylomicron
vldl
howev
acknowledg
cell
differ
enterocyt
multipl
way
data
gener
use
model
interpret
caution
main
differ
cell
deriv
cancer
cell
human
colon
rather
healthi
enter
cell
small
intestin
differ
sure
result
differ
activ
biochem
pathway
addit
cell
synthes
apo
apo
enterocyt
synthes
apo
furthermor
pathway
format
triglycerid
chylomicron
synthesi
differ
cell
enterocyt
use
monoglycerid
pathway
mainli
produc
chylomicron
fat
absorpt
cell
employ
pathway
produc
variou
lipoprotein
chylomicron
major
lipoprotein
produc
anoth
vitro
model
describ
base
good
correl
degre
intestin
lymphat
drug
transport
degre
ex
vivo
associ
drug
chylomicron
obtain
plasma
correl
significantli
better
correl
intestin
lymphat
drug
transport
log
p
triglycerid
solubl
drug
howev
model
wide
adapt
recent
biorelev
test
media
fast
state
simul
intestin
fluid
fassif
fed
state
simul
intestin
fluid
fessif
employ
assess
drug
releas
lipid
base
deliveri
system
howev
describ
section
digest
absorpt
lipid
lipidbas
deliveri
system
follow
emulsif
process
gastrointestin
tract
caus
differ
lipolyt
enzym
releas
drug
abl
pack
chylomicron
entri
lymphat
system
therefor
vitro
model
take
account
lipolysi
lipolysi
model
describ
predict
vivo
absorpt
assess
releas
drug
lipidbas
drug
deliveri
system
assess
whether
drug
precipit
follow
lipolyi
main
purpos
lipidbas
drug
deliveri
system
increas
oral
bioavail
prevent
precipit
poorli
watersolubl
drug
gastrointestin
fluid
howev
order
drug
absorb
enterocyt
lipidbas
deliveri
system
need
keep
drug
solubil
follow
lipolysi
process
thu
design
lipidbas
deliveri
system
need
account
perform
vivo
lipolysi
ensur
drug
remain
solubil
precipit
failur
take
account
lead
success
failur
deliveri
system
improv
drug
absorpt
vitro
lipolysi
model
becom
use
assess
suitabl
lipidbas
deliveri
system
predict
would
behav
vivo
vitro
lipolysi
model
basic
account
five
main
variabl
occur
vivo
lipolysi
dynam
model
releas
hydroxyl
anion
oh
liber
free
fatti
acid
lipolysi
requir
presenc
counterion
calcium
ca
control
process
rate
lipolysi
regul
presenc
hydrolyt
enzym
lipolysi
occur
regular
bodi
temperatur
upon
lipolysi
complet
digest
fraction
either
solut
determin
whether
fraction
compon
would
absorb
experiment
setup
model
account
vivo
variabl
respect
ph
continu
measur
determin
hydroxyl
anion
releas
measur
extent
lipolysi
held
constant
autoburett
titrat
base
ensur
calcium
present
constantlystir
lipolysi
medium
also
compos
digest
buffer
bile
salt
phosphatidylcholin
ad
biorelev
level
pancreat
lipas
colipas
initi
lipolysi
ad
acid
bbba
termin
lipolysi
maintain
temperatur
water
bath
ultracentrifug
medium
obtain
separ
aqueou
phase
contain
bile
salt
fatti
acid
monoglycerol
lipid
phase
contain
undigest
triglycerid
diglycerid
precipit
sediment
contain
undissolv
fatti
acid
phase
analyz
drug
content
dissolut
drug
intestin
fluid
requir
drug
absorpt
drug
solubil
aqueou
phase
experiment
medium
gener
avail
absorpt
drug
sediment
would
avail
absorpt
vivo
furthermor
model
allow
simul
fast
fed
state
condit
use
differ
concentr
bile
salt
lecithin
experiment
medium
instanc
fast
state
condit
simul
mm
cholat
mm
lecithin
fed
state
condit
simul
mm
cholat
mm
lecithin
theoret
background
technic
detail
found
elsewher
describ
section
anim
model
model
employ
surgeri
postsurgeri
recoveri
period
stress
anim
could
ultim
affect
physiolog
gastrointestin
tract
thu
silico
model
would
desir
provid
simpl
comput
approach
predict
intestin
lymphat
transport
need
model
came
inadequ
correl
vivo
studi
empiricallydetermin
vitro
measur
solubl
base
vivo
studi
observ
lipophil
triglycerid
solubl
correl
well
extent
lymphat
transport
instanc
propos
drug
log
p
valu
n
triglycerid
solubl
n
mgml
would
signific
lymphat
transport
howev
compound
like
penclomedin
log
p
triglycerid
solubl
mgml
lipophil
lipid
regul
log
p
triglycerid
solubl
n
mgml
report
low
lymphat
transport
therefor
observ
lipophil
triglycerid
solubl
correl
lymphat
transport
complet
adequ
adequ
predict
model
need
implement
initi
work
develop
silico
model
intestin
lymphat
transport
base
success
model
passiv
absorpt
recent
quantit
relationship
molecular
structur
degre
intestin
lymphat
drug
lipophil
compound
coadminist
longchain
triglycerid
vehicl
examin
use
comput
program
volsurf
variou
drug
select
use
literatur
valu
intestin
lymphat
drug
transport
molecular
descriptor
calcul
use
volsurf
softwar
base
molecular
structur
render
use
sybyl
molecular
model
system
tripo
inc
log
p
valu
estim
use
onlin
version
logkow
assess
similar
experiment
estim
lymphat
transport
partial
least
squar
project
latent
structur
pl
determin
use
softwar
simcap
statist
analysi
includ
variabl
influenc
project
vip
valu
crossvalid
correl
coeffici
q
pl
analysi
report
intestin
lymphat
transport
drug
estim
base
nine
descriptor
globular
hydrophil
surfac
size
local
interact
minima
fraction
hydrophil
surfac
area
hydrophiliclipophil
ratio
molecul
unbal
center
mass
center
hydrophil
region
molecul
unbal
center
mass
center
lipophil
region
molecul
observ
comput
model
significantli
better
correl
intestin
lymphat
drug
transport
empiricallydetermin
log
p
andor
triglycerid
solubl
drug
even
though
model
success
predict
lymphat
drug
transport
valid
describ
author
initi
model
therefor
appreci
term
silico
model
intestin
lymphat
drug
transport
area
earli
stage
studi
warrant
howev
acknowledg
differ
vitro
silico
model
wide
appli
assess
intestin
drug
absorpt
drug
dissolut
drug
solubl
lymphat
absorpt
pathway
offer
uniqu
advantag
drug
absorb
via
portal
blood
follow
oral
administr
hepat
firstpass
metabol
evad
extent
drug
metabol
usual
involv
varieti
enzym
definit
biochem
perspect
improv
abil
act
catalyst
biotransform
substrat
drug
metabolit
lower
requir
activ
energi
reaction
two
categori
drug
metabol
well
recogn
today
phase
phase
ii
metabol
phase
enzym
catalyz
wide
array
chemic
reaction
howev
common
theme
appar
phase
enzym
reaction
final
product
usual
modifi
contain
function
group
like
hydroxyl
amin
carboxyl
acid
phase
ii
metabol
necessarili
requir
phase
metabol
preced
beforehand
modifi
function
group
glucuronid
glycosid
sulfat
methyl
acetyl
glutathion
conjug
amino
acid
conjug
fatti
acid
conjug
condens
major
research
area
phase
ii
metabol
focus
cytochrom
cyp
udpglucuronosyltransferas
ugt
protein
ugtcatalyz
glucuronid
reaction
respons
drug
metabol
phase
ii
enzym
human
ugt
superfamili
enzym
metabol
via
conjug
varieti
endogen
substrat
includ
bile
acid
fatsolubl
vitamin
drug
ugt
found
bound
intern
membran
face
lumin
side
endoplasm
reticulum
specif
configur
allow
enzym
direct
access
metabolit
form
phase
reaction
previous
describ
drug
transport
intestin
lymphat
system
protect
firstpass
hepat
metabol
mesenter
lymph
unlik
portal
blood
empti
system
circul
without
first
pass
liver
signific
drug
high
presystem
clearanc
like
testosteron
extrem
limit
oral
bioavail
howev
highli
lipophil
prodrug
testosteron
testosteron
undecano
oral
bioavail
enter
well
activ
metabolit
system
compart
via
intestin
lymph
howev
enterocytebas
firstpass
metabol
describ
impact
lymphat
drug
transport
enterocytebas
firstpass
metabol
well
describ
literatur
briefli
benzo
pyren
oral
coadminist
lipid
kilfish
lipid
transport
lymph
lipoporotein
benzo
pyren
dispers
enterocyt
without
associ
lipid
lipoprotein
attribut
format
hydrophil
metabolit
benzo
pyren
smooth
endoplasm
reticulum
caus
readi
absorpt
system
compart
via
portal
circul
instead
via
lymphat
circul
similarli
halofantrin
oral
administ
lymph
ductcannul
rat
lower
transport
rate
lymph
observ
drug
compar
fatti
acid
administ
control
group
appar
halofantrin
remov
lymph
precursor
pool
enterocyt
metabol
halofantrin
desbutylhalofantrin
caus
differ
transport
rate
furthermor
coadministr
appreci
amount
lipid
either
foodderiv
lipid
fed
fatti
meal
direct
lipid
dose
diminish
enterocyt
metabol
sequestr
drug
larger
lipid
droplet
reduc
access
drug
benzo
pyren
halofantrin
metabol
enzym
locat
surfac
smooth
endoplasm
reticulum
although
report
drug
transport
via
intestin
lymphat
system
intestin
lymphat
system
could
util
transport
pathway
lipophil
drug
order
fulli
benefit
lymphat
drug
transport
much
work
requir
gain
knowledg
enterocyt
contribut
separ
lipophil
drug
transport
lymph
versu
portal
circul
lipid
transportprotein
identifi
enterocyt
membran
apic
basolater
membran
famili
intracellular
lipid
bind
protein
also
exist
togeth
facilit
entri
absorpt
movement
across
intracellular
transport
endogen
lipid
lipid
diet
exogen
typic
lipid
enter
enterocyt
via
passiv
diffus
activ
transport
addit
apic
transport
also
identifi
facilit
absorpt
process
exampl
identifi
lipid
transport
protein
furthermor
interest
mention
protein
also
shown
transfer
across
apic
membran
enterocyt
transport
less
well
defin
sever
atpbind
cassett
abc
transport
implic
lipid
uptak
across
plasma
membran
intracellular
lipid
traffick
abc
transport
may
therefor
involv
intestin
lipid
absorpt
although
role
transport
demonstr
exampl
pglycoprotein
pgp
believ
influenc
intestin
lipoprotein
format
suggest
pgp
facilit
absorpt
intracellular
traffick
cholesterol
although
evid
still
circumstanti
addit
appear
facilit
absorpt
cholesterol
across
basolater
membran
enterocyt
plasma
enhanc
format
nascent
high
densiti
lipoprotein
thought
reduc
excess
intestin
cholesterol
sterol
absorpt
facilit
efflux
enterocyt
tabl
summar
differ
predomin
atpbind
cassett
abc
transport
metabol
enzym
famili
modul
lipid
excipientssurfact
associ
known
drug
report
involv
intestin
lymphat
transport
upon
cross
apic
side
intestin
lumen
drug
metabol
phase
phase
ii
describ
detail
section
review
metabolit
well
parent
drug
activ
transport
across
basal
membran
intestin
blood
efflux
back
intestin
lumen
therefor
process
activ
transport
facilit
mani
type
major
activ
transport
protein
pgp
belong
multidrug
resistancetyp
multidrug
resistanceassoci
protein
mrp
organ
anion
transport
togeth
play
major
role
govern
overal
bioavail
food
drug
xenobiot
pglycoprotein
pgp
upon
discoveri
cytotox
drug
destroy
cancer
cell
research
also
discov
drug
resist
multipl
drug
imped
effect
drug
pgp
first
activ
transport
protein
discov
today
know
pgp
recent
identifi
protein
act
efflux
pump
broad
specif
varieti
substrat
pgp
member
larg
divers
famili
member
atpbind
cassett
abc
efflux
protein
substrat
pgp
typic
lipophil
cation
previous
mention
larg
number
compound
substratesinhibitor
pgp
includ
anticanc
agent
antibiot
antivir
calcium
channel
blocker
immunosuppress
agent
plant
chemic
usual
found
normal
diet
natur
pgp
limit
absorpt
certain
compound
efflux
compound
enterocyt
back
lumen
thu
limit
bioavail
data
vitro
vivo
studi
use
human
intestin
epitheli
cell
line
pgpknockout
mice
respect
show
disrupt
pgp
activ
would
lead
potenti
hazard
problem
regard
drug
disposit
typic
substrat
pgp
lipophil
expect
pgp
play
role
lymphat
transport
drug
howev
direct
evid
report
yet
multidrugresist
associ
protein
mrp
mrp
discov
much
later
pgp
gener
current
known
mrp
howev
recent
discov
rel
littl
inform
exist
current
regard
function
express
pattern
substrat
mrp
differ
regard
individu
isoform
well
respect
local
howev
gener
mechanist
function
mrp
current
believ
elimin
compound
cell
via
efflux
studi
shown
class
transport
confer
resist
cytotox
drug
vincristin
peptid
heavi
metal
anion
well
endogen
metabolit
bilirubin
glucuronid
divers
substrat
mrp
handl
would
expect
mrp
play
role
lymphat
transport
drug
howev
direct
evid
report
yet
earli
research
focus
cytochrom
thought
rate
overal
extent
metabol
tabl
predomin
atpbind
cassett
abc
transport
metabol
enzym
famili
report
involv
intestin
lymphat
transport
known
modul
lipid
excipientssurfact
associ
known
drug
lipid
predomin
factor
overal
disposit
drug
subject
biotransform
research
progress
begin
understand
intric
relationship
exist
phase
metabol
enzym
efflux
transport
pgp
interplay
singl
metabol
enzym
andor
transport
relationshipcommun
least
protein
ie
one
metabol
enzym
one
transport
area
activ
research
help
understand
mechan
coupl
one
could
imagin
tradit
onetwo
punch
scenario
compound
enter
enterocyt
quickli
get
metabol
phase
phase
ii
immedi
taken
efflux
transport
efflux
back
across
intestin
lumen
howev
rather
simplifi
onetwo
mechan
observ
report
current
find
literatur
data
suggest
mechan
metabol
enzym
interact
efflux
transport
way
metabol
enzym
interact
well
efflux
transport
transport
gener
connect
highli
complex
simpl
onetwo
process
exampl
doubl
jeopardi
theori
propos
benet
cowork
substrat
assum
absorb
apic
membran
met
cyp
substrat
subject
metabol
thu
term
prosecut
first
time
cyp
respect
efflux
pgp
assum
take
parent
compound
transport
via
efflux
back
intestin
lumen
unmetabol
parent
drug
pass
side
basolater
membran
thu
reach
either
portalor
lymphaticcapillari
intact
parent
drug
return
intestin
lumen
via
efflux
absorb
one
time
apic
side
membran
intestin
tract
thu
subject
metabol
repeat
prosecut
thu
give
term
doubl
jeopardi
theori
consequenti
disrupt
pgp
activ
would
result
less
repeat
chanc
exposur
time
substrat
question
apic
membran
would
lead
substrat
insid
intestin
ie
increas
absorpt
thu
could
potenti
increas
bioavail
substrat
andor
metabolit
system
circul
hand
cyp
activ
disrupt
amount
metabolit
would
decreas
sever
thu
perhap
allow
substrat
reach
system
circul
intact
schemat
represent
doubl
jeopardi
theori
present
fig
lipophil
drug
poor
watersolubl
consequ
tend
low
variabl
absorpt
follow
oral
administr
absorpt
lipophil
drug
intestin
lymphat
portal
circul
follow
oral
administr
often
increas
postprandi
effect
result
coadministr
food
increas
drug
absorpt
food
attribut
multipl
effect
foodderiv
lipid
particularli
longchain
triglycerid
lipid
decreas
rate
gastric
empti
stimul
secret
biliari
lipid
increas
rate
lipolysi
increas
drugtointestin
membran
contact
increas
drug
dissolut
rate
solubil
alter
composit
intestin
fluid
increas
format
triglyceriderich
chylomicron
lipid
digestionreacyl
pathway
glyceriderich
chylomicron
believ
allow
lymphaticallytransport
drug
partit
transport
along
chylomicron
intestin
lymphat
preferenti
associ
administ
lipophil
drug
lipid
digest
reacyl
pathway
result
secret
drugcontain
lipoprotein
intestin
lymphat
thu
common
formul
approach
achiev
either
postor
paraprandi
effect
seen
foodderiv
lipid
replac
foodfor
formulationderiv
lipid
use
combin
lipid
surfact
andor
cosolv
expand
abil
improv
oral
absorpt
addit
mechan
alreadi
mention
foodderiv
lipid
includ
protect
lumin
drug
degrad
enhanc
membran
permeabl
decreas
hepat
firstpass
metabol
optim
lymphat
drug
transport
candid
drug
lipidbas
formul
need
ration
pair
quantiti
lumin
cellular
lipid
gener
limit
drug
coadminist
either
foodor
formulationderiv
lipid
often
solubl
administ
drug
dissolut
triglycerid
limit
lymphat
transport
lipophil
drug
know
drug
need
partit
triglyceriderich
chylomicron
candid
drug
high
solubl
triglycerid
take
primaci
select
candid
drug
charman
et
al
suggest
amount
candid
drug
may
transport
intestin
lymphat
product
quantiti
lipid
transport
lymph
form
chylomicron
amount
drug
per
chylomicron
recogn
concentr
drug
per
chylomicron
influenc
partit
coeffici
triglycerid
solubl
drug
charman
et
al
propos
drug
candid
lymphat
transport
log
p
n
triglycerid
solubl
mgml
howev
combin
high
log
p
high
triglycerid
solubl
necessarili
result
lymphat
transport
mention
earlier
penclomedin
experiment
cytotox
agent
log
p
triglycerid
solubl
mgml
poorli
transport
intestin
lymph
dose
similarli
hauss
et
al
report
low
level
dose
lymphat
transport
use
lipophil
lipid
regul
log
p
triglycerid
solubl
mgml
coadministr
drug
formulationderiv
lipid
perhap
studi
success
approach
increas
lymphat
drug
transport
lipidbas
formul
solut
suspens
selfemulsifi
formul
contain
liquid
semisolid
triglycerid
mix
monoand
diglycerid
surfact
either
alon
mixtur
possibl
combin
hydrophil
cosolv
varieti
effort
standard
descript
lipidbas
formul
pouton
et
al
devis
lipid
formul
classif
system
lfc
recent
publish
updat
version
tabl
although
system
sole
direct
formul
lymphaticallytransport
drug
encompass
formul
suitabl
type
drug
lfc
convey
characterist
potenti
limit
variou
type
formul
achiev
small
particl
size
prone
drug
precipit
intestin
fluid
dilut
formulationderiv
lipid
digest
precipit
lymphaticallytransport
drug
alreadi
requir
lipidbas
formul
dissolv
easili
redissolv
upon
precipit
briefli
type
system
contain
sole
lipid
compon
typic
mixtur
glycerid
littl
solubl
water
system
requir
lipid
digest
facilit
format
colloid
dispers
lipid
lipid
digest
product
lipophil
drug
intestin
bile
saltphospholipid
mix
micel
system
ideal
suit
lymphaticallytransport
drug
high
triglycerid
solubl
type
system
contain
lipid
polar
lipid
water
insolubl
surfact
system
vari
digest
still
enhanc
lipophil
drug
bioavail
achiev
smaller
dispers
achiev
type
system
type
system
stabli
selfemulsifi
dispers
quickli
form
fine
dispers
owe
appreci
amount
surfact
howev
dispers
proce
quickli
system
quickli
lose
solvent
capac
upon
dilut
intestin
fluid
result
drug
precipit
type
system
pure
surfact
mixtur
surfact
cosolv
system
report
use
lymphaticallytransport
drug
likelihood
lipophil
drug
precipit
earli
work
use
system
recent
review
exampl
type
system
also
know
selfemulsifi
drug
deliveri
system
sedd
form
fine
oilinwat
emuls
even
microemuls
smedd
expos
aqueou
media
condit
gentl
agit
commerci
avail
formul
cyclosporin
microemuls
preconcentr
improv
oral
bioavail
reduc
interand
intrasubject
variabl
compar
origin
crude
emuls
product
similar
lipidbas
formul
hiv
proteas
inhibitor
saquinavir
ritonavir
amprenavir
also
reach
market
advantag
formul
includ
eas
product
enhanc
solvent
capac
increas
stabil
potenti
administ
final
product
oral
soft
gelatin
capsul
addit
sedd
typic
produc
emuls
particl
size
nm
smedd
form
transpar
microemuls
particl
size
less
nm
properti
suggest
make
sedd
smedd
good
formul
altern
oral
deliveri
lipophil
drug
exampl
impact
lipidbas
formul
type
vitro
dispers
digest
properti
relationship
oral
bioavail
use
danazol
model
lipophil
poorli
watersolubl
drug
studi
three
lipidbas
danazol
formul
assess
solut
longchain
triglycerid
lctsolut
smedd
base
longchain
c
lipid
lcsmedd
mediumchain
c
lipid
mcsmedd
administ
fast
dog
compar
micron
danazol
formul
either
coadminist
food
fast
lctsolut
lcsmedd
formul
significantli
enhanc
oral
bioavail
danazol
compar
fast
administr
powder
formul
mcsmedd
result
littl
enhanc
danazol
bioavail
support
vivo
find
vitro
digest
mcsmedd
formul
result
signific
drug
precipit
compar
lcsmedd
formul
potenti
util
lipid
enhanc
bioavail
lymphat
transport
gener
assess
consid
structur
featur
lipid
chain
length
lipid
class
degre
satur
howev
consider
amount
formul
lipid
administ
digest
lipid
extent
dispers
also
consid
point
briefli
review
detail
appear
previou
review
perform
lipidbas
formul
increas
absorpt
lymphaticallytransport
drug
base
particular
combin
formul
drug
howev
review
literatur
gener
comment
made
structur
featur
lipid
favor
lymphat
drug
transport
lymphaticallytransport
drug
tend
higher
achiev
peak
concentr
quicker
formul
lipid
requir
minim
digest
prior
enter
lipid
digestionreacyl
pathway
accordingli
fatti
acid
use
place
triglycerid
phospholipid
need
preabsorpt
hydrolysi
addit
lymphat
drug
transport
increas
use
monounsatur
polyunsatur
fatti
acid
part
larger
lipoprotein
use
satur
fatti
acid
increas
degre
fatti
acid
unsatur
lagtim
signific
increas
chylomicron
concentr
reduc
compar
control
cheema
et
al
hypothes
differ
onset
chylomicron
synthesi
probabl
reflect
rapid
rate
absorpt
tabl
lipid
formul
classif
system
characterist
featur
advantag
disadvantag
four
essenti
type
lipid
formul
reproduc
pouton
porter
increas
fatti
acid
unsatur
addit
greater
degre
unsatur
fatti
acid
lower
melt
point
greater
fluiditi
less
hydrophob
molecul
factor
facilit
absorpt
final
lymphat
drug
transport
gener
enhanc
lipid
formul
base
long
c
chain
lipid
oppos
mediumchain
c
shortchain
c
lipid
fatti
acid
chain
length
primarili
transport
intestin
lymph
shorterchain
fatti
acid
primarili
transport
portal
blood
process
digest
especi
rate
digest
rel
transit
time
formul
drug
absorpt
site
increas
decreas
capac
formulationderiv
lipid
solubil
lipophil
drug
understand
digest
formulationderiv
lipid
maintain
drug
solut
intestin
fluid
one
need
understand
interact
drug
digest
formulatedlipid
end
product
formulatedlipid
digest
lipidrich
bile
saltphospholipid
mix
micel
lipolyt
product
lipid
lipidbas
formul
gener
expos
intestin
fluid
contain
lipas
bile
salt
secret
pancrea
gall
bladder
respect
lipolysi
multilamellar
liquid
crystallin
intermedi
phase
greater
polar
initi
formulatedlipid
build
surfac
degrad
lipid
droplet
despit
differ
polar
hydrophob
continuum
exist
go
surfac
dispers
degrad
lipid
droplet
interior
contain
intermedi
product
phase
continuum
allow
lipophil
drug
remain
solubil
allow
drug
migrat
dispers
degrad
lipid
droplet
liquid
crystallin
phase
continu
broken
action
bile
salt
micel
lead
format
end
product
formulatedlipid
digest
lipidrich
bile
saltphospholipid
mix
micel
mix
micel
drug
solubl
proport
bile
salt
concentr
increas
lipophil
drug
solubl
increas
log
p
drug
minimum
log
p
remain
solut
consequ
lymphaticallytransport
lipophil
drug
alreadi
defin
logp
n
expect
remain
solut
whether
administ
digest
formulationderiv
lipid
droplet
end
product
mix
bile
saltphospholipid
micel
provid
strong
solubil
environ
lipophil
drug
mix
micel
provid
sourc
freeli
diffus
drug
enterocyt
uptak
intestin
wall
solubil
drug
mix
micellar
phase
bile
salt
lipolyt
digest
product
increas
lumin
solubl
ordersofmagnitud
well
facilit
passag
unstir
layer
therebi
enhanc
quantit
aspect
absorpt
hydrophil
surfact
inhibit
significantli
lipolysi
triglycerid
compon
screen
exercis
identifi
cremophor
commonli
use
hydrophil
ethoxyl
triglycerid
surfact
complet
inhibit
lipolyi
mct
oil
min
period
vitro
oil
surfact
present
equal
mass
addit
third
compon
lipophil
surfact
case
caus
recoveri
lipolyi
may
conclud
low
particl
size
inevit
lead
better
bioavail
perform
lipidbas
deliveri
system
govern
fate
gastrointestin
tract
rather
particl
size
initi
dispers
gener
dispers
formul
typic
prefer
whether
dispers
nondispers
selfemulsifi
reason
expect
rate
lipophil
drug
diffus
dispers
oil
phase
aqueou
intestin
fluid
govern
solut
mix
micel
rate
structur
form
lipolysi
sinc
latter
interfaci
process
rate
lipolysi
depend
size
emuls
particl
therefor
necessari
maxim
rate
drug
partit
aqueou
intestin
fluid
henc
absorpt
rate
formul
highli
dispers
accordingli
maxim
lymphaticallyabsorb
lipophil
drug
lipidbas
formul
prepar
mix
micellar
system
possibl
crude
emuls
still
possibl
lipid
solut
drug
transport
via
intestin
lymphat
gener
enhanc
increas
lipid
amount
shown
rat
follow
administr
cholesterol
undecano
oleic
acid
result
signific
lag
time
seen
administ
lipid
vehicl
like
result
prolong
gastric
empti
result
larg
lipid
load
provid
higher
dose
volum
howev
amount
coadminist
lipid
limit
ensur
proper
digest
intestin
lumen
prior
enterocyt
uptak
report
dose
volum
thu
dose
amount
particular
lipid
signific
effect
intestin
lymphat
transport
benzo
pyren
oliv
oil
ddt
variou
lipid
although
effect
dose
volum
cumul
lymphat
transport
dichlorodiphenyltrichloroethan
ddt
concentr
ddt
per
chylomicron
proport
higher
administ
compar
lipid
vehicl
suggest
chylomicronmedi
transport
becam
satur
finit
solubl
drug
triglycerid
core
chylomicron
like
last
studi
vivo
studi
lipid
effect
lymphaticallytransport
drug
gener
done
rat
use
wide
vari
sometim
excess
lipid
volum
ml
use
lower
volum
equival
dose
human
base
bodi
weightadjust
ml
lipid
howev
lipidbas
formul
given
human
typic
dose
volum
millilit
although
administ
lipid
excess
rat
fortun
effect
lipid
often
relev
human
effect
human
seen
low
lipid
amount
influenc
oral
administr
three
lipidbas
formul
neg
control
formul
gastric
empti
biliari
secret
evalu
human
subject
use
gamma
scintigraphi
ultrasonographi
duoden
aspir
shown
littl
g
longchain
lipid
lower
gastric
empti
stimul
gall
bladder
contract
elev
intestin
bile
salt
phospholipid
cholesterol
level
similar
chang
observ
similar
quantiti
mediumchain
lipid
administ
therefor
quantiti
longchain
lipid
might
administ
pharmaceut
formul
could
expect
stimul
gall
bladder
contract
elev
intestin
level
bile
salt
phospholipid
lipid
prodrug
compris
drug
coval
bound
lipid
fatti
acid
monoglycerid
diglycerid
phosphoglycerid
rational
use
lipid
prodrug
increas
lymphat
transport
previous
review
attempt
ensur
increas
log
p
triglycerid
solubl
parent
drug
glyceriderich
chylomicron
albeit
covalentassoci
prodrug
chemist
synthes
prodrug
increas
lipophil
prodrug
compar
parent
drug
use
simpl
ester
longchain
fatti
acid
howev
approach
limit
success
due
ubiquit
esteras
peptidas
present
organ
bodi
particularli
activ
intestin
tract
intestin
cell
liver
capabl
cleav
ester
prodrug
consequ
high
probabl
ester
prodrug
would
lose
enzymelabil
chemic
function
well
advanc
transit
intestin
fluid
associ
enterocytederiv
chylomicron
still
transit
lymphat
fail
remain
intact
net
effect
better
parent
drug
administ
first
place
provid
parent
drug
metabol
stabl
substrat
efflux
transport
nevertheless
ester
ether
linkag
use
increas
lipophil
testosteron
fat
solubl
vitamin
c
nonsteroid
antiinflammatori
drug
nsaid
effort
get
prodrug
particip
lipid
digest
biochemistri
pathway
three
differ
lipid
carrier
gener
use
fatti
acid
glycerid
phospholipid
fig
sinc
triglycerid
absorb
intact
pancreat
lipas
driven
drug
deliveri
metabol
initi
produc
symmetr
two
fatti
acid
fatti
acid
substitu
place
drug
place
possibl
gener
drugattach
pseudoglycerid
lipas
rapidli
hydrolyz
ester
glycerol
backbon
slow
therefor
lipid
prodrug
drug
attach
either
ester
bond
drug
bear
carboxyl
group
spacer
function
present
releas
lipas
glycerol
backbon
monoglycerid
fatti
acid
enter
enterocyt
longchain
fatti
acid
c
n
reesterifi
triglycerid
addit
activ
fatti
acid
posit
exampl
monoglycerid
prodrug
nsaid
naproxen
acetaminophen
synthes
reduc
advers
side
effect
includ
stomach
ulcer
bleed
perfor
increas
oral
bioavail
oral
administr
ester
naproxen
result
increas
recoveri
total
prodrug
drug
recov
lymph
rel
administr
parent
drug
howev
intestin
lymphat
transport
rate
naproxen
increas
approxim
dose
dose
nalkyl
chain
introduc
glycerol
backbon
drug
acetaminophen
similarli
increas
dose
unexpectedli
intestin
lymphat
transport
triglycerid
deriv
drug
combin
directli
glycerol
low
comparison
monoglycerid
prodrug
although
author
give
reason
differ
possibl
select
palmit
acid
satur
fatti
acid
less
favor
increas
lymphat
transport
triglycerid
polyunsatur
fatti
acid
khan
et
al
taken
diglycerid
prodrug
approach
set
prodrug
diclofenac
ibuprofen
mefenam
acid
prodrug
synthes
dipalmit
stearat
glycerid
deriv
glycerol
backbon
parent
drug
backbon
prodrug
resist
show
less
hydrolysi
ph
condit
might
consid
relev
gastric
condit
ph
howev
facil
releas
parent
drug
observ
ph
condit
might
consid
relev
intestin
condit
ph
peak
plasma
concentr
parent
drug
higher
delay
prodrugdos
parent
drugdos
rat
prodrug
show
less
frequent
sever
gastric
ulcer
compar
parent
drug
prodrug
show
better
antiinflammatori
activ
compar
parent
drug
analges
activ
compar
parent
drug
taken
togeth
studi
show
prodrug
way
increas
bioavail
decreas
gastrointestin
side
effect
nsaid
concept
phospholipid
prodrug
help
circumv
presystem
clearanc
follow
biochemistri
normal
phospholipid
bodi
phospholipid
hydrolyz
small
intestin
lysophospholipid
absorpt
enterocyt
enter
reacyl
pathway
similar
reacyl
pathway
glycerid
rather
incorpor
glyceriderich
chylomicron
reacyl
phospholipid
associ
stabil
surfac
chylomicron
report
exampl
phospholipid
prodrug
releas
parent
drug
directli
shown
lymphaticallytransport
earli
exampl
phospholipid
prodrug
approach
sakai
et
al
synthes
dipalmitoyl
phospholipid
prodrug
antitumor
agent
fluorouridin
prodrug
approach
need
fluorouridin
small
polar
drug
would
expect
lymphaticallytransport
expos
cancer
cellrich
lymph
node
minim
system
exposur
result
toxic
prodrug
dipalmitoylphosphatidylfluorouridin
dppf
oral
dose
rat
extent
dppf
two
metabolit
fluorouridin
fur
fluorourcacil
lymphaticallytransport
assess
lymph
blood
concentr
dppf
fur
low
dppf
lymph
concentr
higher
blood
demonstr
prodrug
lymphotrop
dppf
contrast
low
blood
lymph
concentr
dppf
high
level
dppf
congen
differ
respect
posit
group
measur
higher
lymph
blood
congen
shown
arachidonylphosphatidylfluorouridin
papf
plpf
differ
dppf
congen
group
data
suggest
dppf
digest
reacyl
prior
incorpor
onto
chylomicron
secret
lymph
given
suffici
time
author
expect
congen
hydrolyz
lymphat
result
releas
phosphatederivat
drug
activ
form
dahan
et
al
recent
studi
use
phosphatidylcholin
ester
prodrug
antiepilept
drug
valproic
acid
prodrug
dpvpa
valproic
acid
directli
conjug
phospholipid
posit
thu
suscept
enzymat
cleavag
phospholipas
pla
howev
administr
prodrug
mice
either
homozygouslydefect
gene
normal
gene
balbc
show
differ
dpvpa
plasma
exposur
stabil
confirm
absenc
vitro
dpvpa
degrad
serum
low
degrad
bee
venom
pla
dpvpa
administ
fast
rat
dissolv
longchain
triglycerid
lct
c
versu
mediumchain
triglycerid
mct
c
plasma
exposur
increas
time
achiev
peak
concentr
plasma
delay
author
suggest
signific
food
effect
could
result
improv
dissolut
solubil
drug
intestin
fluid
well
intestin
lymphat
transport
combin
observ
food
effect
increas
absorpt
follow
administr
lct
known
simul
chylomicron
product
support
notion
intestin
lymphat
transport
lymphat
transport
evalu
mesenter
lymph
duct
cannul
freeli
move
rat
shown
absorb
dpvpa
associ
lymphat
transport
result
confirm
lymphat
transport
dpvpa
least
dog
develop
lipidbas
formul
ideal
excipi
would
enhanc
drug
solubl
stabil
would
pharmacolog
inert
howev
increas
evid
suggest
excipi
effect
drug
metabol
interact
cellular
transport
research
shown
inhibitori
abil
surfact
regul
express
function
capac
variou
cyp
isoform
specif
polyoxyethylatedpegyl
surfact
cremophor
polysorb
eg
tween
tween
well
polym
identifi
inhibitor
isozym
inhibit
case
appar
express
molecular
level
andor
intrins
metabol
activ
function
capac
accordingli
surfact
necessarili
consid
inert
may
significantli
alter
drug
metabol
excipi
use
lipidbas
formul
found
interruptmodul
efflux
transport
protein
activ
cyp
inhibitedmodul
via
certain
lipidbas
excipi
excipi
simultan
affect
cyp
isoform
typic
well
efflux
transport
ie
pgp
excipi
found
modul
efflux
transport
pgp
level
includ
enzymeprotein
alter
eg
disrupt
drug
bind
regul
express
ie
amount
protein
expressedpres
function
function
capac
ie
intrins
activ
rate
exampl
lipid
excipi
modul
specif
effect
express
efflux
transport
ie
pgp
seen
use
cell
monolay
demonstr
signific
decreas
pgp
efflux
activ
like
due
decreas
express
howev
clear
observ
decreas
pgp
efflux
sole
attribut
decreas
express
anoth
exampl
nonion
deterg
eg
triton
shown
prevent
drug
bind
thu
modul
function
capac
pgp
howev
true
mechan
modul
express
also
impact
due
sequenti
regul
pgp
anoth
exampl
differ
modul
caus
differ
excipi
seen
fatti
acid
ester
surfact
eg
cremophor
el
excipi
pgp
activityexpress
modul
due
alter
drug
bind
like
caus
mutat
transmembran
domain
critic
proper
dock
substrat
efflux
addit
polym
pluron
block
copolym
also
shown
inhibit
pgp
howev
addit
aspect
modul
also
observ
monolay
experi
permeabl
apic
basolater
increas
mention
earlier
efflux
transport
protein
pgp
share
mani
similar
respect
function
broad
substrat
overlap
local
apic
side
enterocyt
tissu
distribut
express
pattern
therefor
surpris
lipid
excipi
also
effect
transport
jia
et
al
recent
demonstr
treat
cell
inhibit
efflux
furthermor
treatment
use
observ
caus
nonspecif
downregul
express
previous
mention
enzym
ie
efflux
transport
ie
pgp
intric
relat
ie
coupl
therefor
plausibl
effectmodul
exampl
abl
directli
andor
indirectli
measur
decreas
efflux
sever
publish
studi
lipid
excipi
found
seddssmedd
abl
inhibit
metabol
efflux
recent
studi
aspect
coupl
eg
presystem
metabol
investig
found
compound
halofantrin
coadminist
lipid
lipid
excipi
andor
metabol
inhibitor
eg
ketoconazol
inhibit
howev
worthwhil
note
inhibit
metabol
plausibl
increas
function
capac
ie
increas
intrins
rate
activ
follow
increas
express
compens
elimin
compound
question
therefor
inhibit
metabol
might
translat
observ
ie
vivo
effect
effect
critic
design
vitro
studi
studi
aim
investig
coupl
target
mani
compon
coupl
machineri
lymphat
drug
transport
report
contributor
oral
bioavail
variou
lipophil
drug
xenobiot
oral
administr
dexabinol
moxidectin
halofantrin
mepitiostan
testosteron
deriv
penclomedin
naftifin
probucol
cyclosporin
ontazolast
retinoid
fat
solubl
vitamin
lycopen
ddt
analog
benzopyren
polychlorin
biphenyl
pcb
variou
lipophil
drug
also
small
number
hydrophil
drug
salicyl
acid
isozianid
caffein
recov
small
quantiti
lymph
oral
administr
instanc
case
ddt
halofantrin
lipophil
lipid
regul
discrep
oral
bioavail
cannul
rat
sum
lymph
concentr
system
blood
concentr
noncannul
rat
system
blood
concentr
cannul
rat
exhibit
higher
bioavail
indic
lack
mass
balanc
total
absorpt
discrep
could
result
chang
clearanc
due
either
drug
accumul
adipos
tissu
presystem
clearanc
drug
lymph
lymphoid
tissu
clearanc
chylomicronbound
drug
increas
upon
entri
system
circul
howev
exact
mechan
chang
oral
bioavail
occur
still
need
elucid
case
human
growth
hormon
follow
subcutan
administr
sheep
discrep
observ
fraction
administ
dose
collect
peripher
lymph
via
effer
duct
poplit
lymph
node
collect
central
lymph
collect
via
thorac
duct
discrep
cumul
lymphat
transport
could
explain
enzymat
degrad
human
growth
hormon
effer
poplit
node
thorac
lymph
duct
thu
exact
mechan
still
elucid
acknowledg
drug
low
bioavail
occurr
lymphat
transport
even
extent
less
administ
dose
significantli
affect
cumul
plasma
exposur
furthermor
recommend
drug
pharmacolog
target
lymphat
system
degre
lymphat
transport
express
concentr
drug
lymph
rather
use
percentag
administ
dose
especi
differ
oral
bioavail
cannul
noncannul
anim
tabl
summar
drug
report
present
differ
degre
intestin
lymphat
transport
increas
develop
highli
lipophil
drug
coupl
increas
interest
understand
mechan
drug
access
lymph
caus
newli
found
interest
intestin
lymphat
drug
transport
recogn
suitabl
altern
enhanc
bioavail
system
exposur
high
liver
firstpass
metabol
drug
initi
gain
access
system
circul
without
pass
liver
multipl
formul
approach
develop
enhanc
lymphat
transport
drug
also
better
understand
cellular
level
digest
uptak
intracellular
metabol
packag
foodderiv
lipid
drug
chylomicron
intestin
lymphat
drug
transport
process
enterocyt
metabol
impact
coadministr
variou
formulationderiv
lipid
excipi
studi
warrant
address
issu
also
identifi
novel
applic
process
